Haemonetics Corporation, a healthcare company, offers medical products and solutions. The company is headquartered in Boston, Massachusetts.
| Revenue (TTM) | $1.35B |
| Gross Profit (TTM) | $802.16M |
| EBITDA | $358.79M |
| Operating Margin | 17.90% |
| Return on Equity | 11.20% |
| Return on Assets | 6.60% |
| Revenue/Share (TTM) | $29.08 |
| Book Value | $18.41 |
| Price-to-Book | 5.81 |
| Price-to-Sales (TTM) | 3.54 |
| EV/Revenue | 4.298 |
| EV/EBITDA | 9.36 |
| Quarterly Earnings Growth (YoY) | 2.90% |
| Quarterly Revenue Growth (YoY) | 5.60% |
| Shares Outstanding | $45.50M |
| Float | $44.89M |
| % Insiders | 1.26% |
| % Institutions | 112.55% |
Volatility is currently contracting
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Haemonetics (HAE). But which of these two stocks presents investors with the better value opportunity right now?
Payment follows approximately $5 million received in January 2026, bringing total cash proceeds received to approximately $11 million Company remains eligible for up to approximately $10 million in additional proceeds through future revenue earnouts Monetization of a strategic holding provides additional capital to advance Orchestra BioMed's pivotal programs and reflects its approach to creating value through partnerships NEW HOPE, Pa., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced the receipt of $6.1 million on September 14, 2026, as the first milestone payment in connection with the previously announced acquisition of Vivasure Medical Limited (“Vivasure”) by Haemonetics Corporation (NYSE: HAE, “Haemonetics”).
Investors with an interest in Medical - Products stocks have likely encountered both GE HealthCare Technologies (GEHC) and Haemonetics (HAE). But which of these two stocks is more attractive to value investors?
CRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation, late-stage catalysts and promising early-stage programs.
Haemonetics is a medtech company that's increasingly generating more recurring revenues with plasma consumables. HAE also has MedSurg, which generates higher margins by selling technologies useful for cardiovascular procedures, for example. As such, these two segments give HAE a durable growth profile. And their recent agreement with CSL could expand on this potential.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Haemonetics raises fiscal 2027 revenue guidance after Q1 earnings and sales beat, supported by Plasma growth and stronger cash generation.
Examine Haemonetics' (HAE) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on HAE and any ticker you trade — then tracks every position and per-strategy win rate.
